GlassScriptPhysician profile
David Burnell Mcgraw
NPI 1336193135
$5,197.89
in general payments reported to CMS, 2019-2025
22 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $765 · 2021: $679 · 2022: $574 · 2023: $617 · 2024: $630 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,645.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,026.09 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $526.27 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.37 | 2019-2025 | Jardiance |
| Pfizer INC. | $359.15 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $281.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $264.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $240.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $102.88 | 2019-2024 | |
| Amgen INC. | $50.83 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $45.83 | 2022-2024 | |
| Abbott Laboratories | $39.15 | 2021-2022 | |
| Exact Sciences Corporation | $35.97 | 2024-2025 | Cologuard Collection Kit |
| Averitas Pharma INC. | $25.63 | 2025 | Qutenza |
| Phathom Pharmaceuticals, INC. | $25.19 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.52 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $20.98 | 2020 | |
| Allergan, INC. | $18.11 | 2019 | |
| Ardelyx, INC. | $16.60 | 2024 | Ibsrela |
| Genentech USA, INC. | $16.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.29 | 2023 | |
| Astellas Pharma US INC | $12.99 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mcgraw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.